Cell membrane lipid composition modulation

Cell membrane lipid composition modulation refers not to a single molecular entity but rather the **therapeutic strategy** or process aimed at altering the types, amounts, or organization of lipids within cellular membranes—especially the plasma membrane. The **lipid bilayer** is composed primarily of phospholipids with significant contributions from cholesterol and glycolipids; its precise composition determines key physical properties such as fluidity, permeability barrier function, lateral domain formation (\"lipid rafts\"), charge asymmetry between leaflets, protein localization/activation sites (e.g., PKC binding), signal transduction efficiency, apoptosis susceptibility, immune recognition potential—and thus overall cell fate.[1][2][5] \n\nIn oncology research especially (\"membrane-lipid therapy\"), differences between normal versus tumor cell membranes are exploited by drugs that modify raft structure/composition—either directly by extracting/inserting certain lipids or indirectly via enzyme inhibition—to disrupt pro-survival signaling platforms unique to cancer cells. This can increase chemosensitivity or trigger programmed cell death.[3] However, because these interventions target fundamental aspects shared across all eukaryotic cells' membranes—not just those found on tumors—there are significant challenges regarding selectivity and safety.\n\nThis entry is considered \"incorrect\" as a canonical drug target because it describes a **therapeutic approach/process**, not an individual gene/protein/receptor/enzyme typically catalogued as a molecular target. It should be replaced with more specific targets such as \"Cholesterol,\" \"Sphingomyelin synthase,\" \"Phosphatidylserine flippase,\" etc., depending on context.

Other names

Membrane-lipid therapyModulation of membrane lipid compositionLipid bilayer modulationPlasma membrane lipid remodeling

- Alteration of cholesterol/sphingolipid content to disrupt lipid rafts and microdomains, affecting receptor clustering and signal transduction in cancer cells[3]\n- Changing biophysical properties of the plasma membrane to sensitize tumor cells to chemotherapeutic agents or induce apoptosis[3][4]\n- Inhibition or activation of enzymes involved in biosynthesis/degradation/transportation of specific lipids, leading to changes in cellular phenotype and function[4]